|
KMID : 0366219870220010037
|
|
Korean Journal of Hematology
1987 Volume.22 No. 1 p.37 ~ p.42
|
|
|
The Effect of Gabexate Mesilate (FOY®) on the Treatment of Disseminated Intravascular Coagulation Associated with Acute Promyelocytic Leukemia
|
|
이홍복/H B Lee
김병국/이영열/김승택/허대석/박선양/김노경/B K Kim/Y Y Lee/S T Kim/D S Huh/S Y Park/N K Kim
|
|
|
Abstract
|
|
|
Gabexate mesilate is a new synthetic serine protease inhibitor which also inhibits
several coagulation factors. Gabexate mesilate has still an inhibitory capacity on the
coagulation cascade in the abscence of antithrombin-Ⅲ, whereas heparin does not.
This is a clinical trial of Gabexate mesilate for the treatment of disseminated
intravascular coagulation (DIC) associated with acute promyelocytic leukemia.
The results are as follows.
1. All 18 patients has clinical symptoms or laboratory evidence of DIC.
2. In control group, all 6 patients were expired within 10 days due to DIC. In heparin
treated group, 2 out of 4 patients were expired within 4 days due to DIC. In Gabexate
mesilate treated group, all 8 patients could overcome DIC. 2 out of 8 patients were
expired due to thrombocytopenia, ie delayed bone marrow recovery. 2 out of 8 patients
were expired due to sepsis.
3. No remarkable side effects of Gabexate mesilate were observed.
We conclude that Gebexate mesilate is very effective in treating DIC associated with
acute promyelocytic leukemia.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|